GRI
GRI Bio, Inc.
Next earnings Aug 12, 2026 · consensus $-1.36 EPS
Last earnings -4.9% on 2026-05-14
$1.82
▲ 0.00%$1.82▼ -95.04%
over 1Y
L $1.82EODHDH $63.28
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W-2.7%
1M-13.3%
3M-20.2%
YTD-76.8%
1Y-95.0%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 6 analysts
Buy
Conservative balance sheet (liabilities/equity 0.44x); but revenue fell -100.0% YoY.
Revenue (FY2021) $0.00 · FY2021
GRI Bio, Inc. shows $0.00 in FY2021 revenue (-100.0% YoY), and -199.0% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $0.00 | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$9.26M | -$2.24M | -$11.4M | -$8.23M | -$12.0M |
| Net income | -$9.30M | -$3.22M | -$13.0M | -$8.21M | -$12.0M |
| Diluted EPS | -$1.42 | -$24.95 | -$5,018.09 | -$1,545.55 | -$121.80 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$5.60M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-454.6%
FCF yield-387.4%
Quality & risk
ROIC (est.)-157.5%
Free cash flow-$10.2M
Total debt—
Net cash$8.23M
Altman Z-Score-11.49 distress
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+175.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-182026-06-18open ↗8-KPeriod ending 2026-05-142026-05-14open ↗SCHEDULE 13G/AFiling2026-05-13open ↗10-QPeriod ending 2026-03-312026-05-13open ↗SCHEDULE 13G/AFiling2026-02-13open ↗SCHEDULE 13G/AFiling2026-02-10open ↗8-KPeriod ending 2026-02-042026-02-04open ↗EFFECTFiling2026-01-30open ↗CORRESPFiling2026-01-30open ↗UPLOADFiling2026-01-30open ↗10-KPeriod ending 2025-12-312026-01-30open ↗8-KPeriod ending 2026-01-292026-01-30open ↗
Frequently asked
- Is GRI Bio, Inc. (GRI) a buy?
- GRI currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.44x); but revenue fell -100.0% YoY.
- What is GRI Bio, Inc.'s quality score?
- GRI scores 35.46153846153846/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001824293, latest 10-Q filed 2026-05-13) · EODHD · as of 6/25/2026, 6:09:15 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.